Session 3
Wednesday, 30 September 2020 | 14:00-15:30 | Room 1
Equitable and sustainable access to safe, effective, affordable and quality assured medicines and health products is critical to Universal Health Coverage and achieving the Sustainable Development Goals (SDG).
Despite this goal being shared by the public and private sectors, achieving it has proved difficult. Patients, health systems and governments expect the right to reasonably priced pharmaceuticals that meet their needs, whilst investors and the pharmaceutical industry expect to earn sufficient profits to compensate for the risk inherent in developing or manufacturing those medicines. Achieving this elusive goal will require much more unity, transparency and coherence between the public and private sectors on a number of controversial topics and sustainability is critical.
The COVID-19 pandemic has demonstrated that this collaboration is possible and panel members will explore how the lessons learnt can be built upon. Participants will also launch a new initiative highlighted in the new WHO European Programme of Work “United Action for Better Health”. The initiative will provide a platform for member States and stakeholders to collaborate and set out a new vision for better access, and consultations and high-level meetings will follow over the course of 2021 and 2022 and seek commitments for joint action to ensure that the dance does not leave anyone behind.